XBKK
THGn
Market cap212mUSD
Jul 26, Last price
25.00THB
Name
Thonburi Healthcare Group PCL
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Thonburi Healthcare Group Public Company Limited, alongside its affiliated entities, manages private hospitals throughout Thailand. The company's operations are divided into three primary segments: Medical Services, Healthcare Solution Provision, and Other Businesses. It offers a comprehensive range of medical treatments, encompassing specialized care in neurosciences, orthopedics, gastroenterology, cardiology, and obstetrics and gynecology. Additionally, the group provides management expertise for provincial government hospitals and heart centers across both public and private sectors. Its varied business interests also include offering elder care and senior living facilities, in-home healthcare services, and operating patient rehabilitation centers. Furthermore, the company engages in real estate development for senior housing, oversees elderly care facilities, and distributes a wide array of dental supply brands such as Adec, W&H, AO, Heraeus, Ivoclar, Megagen, SAM, Melag, and Alpro. Other ventures involve the retail sale of pharmaceuticals and medical supplies in specialized outlets, the creation of hospital management software, and broader property development. Thonburi Healthcare Group operates a network of hospitals that includes four facilities in or near Bangkok (Thonburi, Thonburi 2, Thonburi Bamrungmuang, and Thonburi Burana Hospital in Pathum Thani), four provincial hospitals (Rajyindee, Ubonrak Thonburi, Sirivej Chanthaburi, and Thonburi Thungsong), and one international hospital located in the Republic of the Union of Myanmar. Founded in 1976, the company maintains its headquarters in Bangkok, Thailand.
Valuation
Title THB in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||